Why did 4596.T stock fall so sharply today?

The drop reflects heightened concern about Phase III and Phase II clinical timing for emixustat and related trial risk, combined with heavy intraday selling and a large volume spike of **23,256,500.00** shares on JPX.

What is the Meyka AI view for 4596.T stock?

Meyka AI rates 4596.T **68.03** (Grade B, HOLD) and its forecast model projects a monthly target of **¥212.66**, implying **+30.48%** vs the current **¥163.00**; forecasts are model-based and not guaranteed.

Is Kubota financially able to fund development after the drop?

Kubota shows **cash per share ¥27.93** and a current ratio indicating liquidity, which provides a buffer. However, negative operating cash flow per share and development costs mean funding risk remains material.

How should traders treat 4596.T stock in the short term?

Treat the stock as high-volatility. Intraday action shows momentum and trend strength, but clinical news can swing price sharply. Use tight risk controls and monitor JPX trade volume and official trial updates.

JP Stocks

4596.T Kubota Pharmaceutical (JPX) -30.93% to ¥163 Mar 2026: catalyst risk

ByHuzaifa Zahoor March 3, 2026March 3, 2026

The 4596.T stock tumbled intraday after a heavy selloff, falling -30.93% to ¥163.00 on JPX on Mar 2026. Traders hit the bid from the open ¥215.00, leaving a session low of ¥160.00 on volume of 23,256,500.00 shares. The move makes Kubota Pharmaceutical Holdings Co., Ltd. an intraday top loser as investors reassess Phase III drug risk and near-term funding needs. Meyka AI-powered market analysis platform flagged the move for active traders and institutional scanners.